Publicado 03/06/2018 14:31
- Comunicado -

Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018 (2)

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of EUR 15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

References 

1) American Cancer Society (2015) Global facts & figures third edition. Available from: http://www.cancer.org/acs/groups/content... . [http://www.cancer.org/acs/groups/content... ] Accessed February 2018 2) American Cancer Society (2017) Key statistics for lung cancer. Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/abo... . Accessed February 2018. 3) American Cancer Society (2016) What is non-small cell lung cancer? Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/abo... . Accessed February 2018. 4) Cancer.net. Lung cancer - non-small cell: statistics. Available from: http://www.cancer.net/cancer-types/lung-cancer-non-small-cel.... Accessed February 2018. 5) Lutterbach B et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. (2007) 67(5):2081-8. 6) Wong MCS, et al. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci. Rep. (2017) 7:143000: doi: 10.1038/s41598-017-14513-7. [https://www.nature.com/articles/s41598-017-14513-7 ]

Contact: Brenda Mulligan +978-821-5345

(Logo: http://photos.prnewswire.com/prnh/201512... )

Photo: http://photos.prnewswire.com/prnh/201512...

Contenido patrocinado